公开(公告)号：US10603314B2

公开(公告)日：2020-03-31

申请号：US11883474

申请日：2006-02-02

申请人： Daniel A. Haber ,  Daphne Winifred Bell ,  Jeffrey E. Settleman ,  Raffaella Sordella ,  Nadia G. Godin-Heymann ,  Eunice L. Kwak ,  Sridhar Krishna Rabindran

发明人： Daniel A. Haber ,  Daphne Winifred Bell ,  Jeffrey E. Settleman ,  Raffaella Sordella ,  Nadia G. Godin-Heymann ,  Eunice L. Kwak ,  Sridhar Krishna Rabindran

IPC分类号： A61K31/4709 ,  A61K31/4706 ,  A61K31/17 ,  A61K38/17

摘要： The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

公开(公告)号：US20100087482A1

公开(公告)日：2010-04-08

申请号：US11883474

申请日：2006-02-02

申请人： Daniel A. Haber ,  Daphne Winifred Bell ,  Jeffrey E. Settleman ,  Raffaella Sordella ,  Nadia G. Godin-Heymann ,  Eunice L. Kwak ,  Krishna Rabindran

发明人： Daniel A. Haber ,  Daphne Winifred Bell ,  Jeffrey E. Settleman ,  Raffaella Sordella ,  Nadia G. Godin-Heymann ,  Eunice L. Kwak ,  Krishna Rabindran

IPC分类号： A61K31/4706 ,  A61P35/00 ,  A61K31/4709

CPC分类号： A61K31/4709 ,  A61K31/4706 ,  A61K38/17

摘要： The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

摘要翻译： 本发明涉及用于治疗吉非替尼和/或厄洛替尼耐药性癌症的方法。 在用吉非替尼和/或厄洛替尼治疗后，监测癌症患者的癌症发展。 癌症的进展表明癌症对吉非替尼和/或厄洛替尼具有抗性。 一旦注意到癌的进展，给予受试者包含不可逆表皮生长因子受体（EGFR）抑制剂的药物组合物。 在优选的实施方案中，不可逆EGFR抑制剂是EKB-569，HKI-272和HKI-357。